TNF-α's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression

Journal of Bone and Mineral Research

Volumn 25, Issue 7, 2010, Pages 1616-1626

  Ghali, Olfa ^a   Chauveau, Christophe ^a   Hardouin, Pierre ^a   Broux, Odile ^a   Devedjian, Jean Christophe ^a  

^a UNIV LILLE   (France)

Author keywords

Apoptosis; hMSCs; Proliferation; RUNX2; TNF

Indexed keywords

CASPASE 3; CYCLIN A1; CYCLIN B1; CYCLIN E; CYCLIN E1; PROTEIN BAX; PROTEIN P21; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION;

EID: 77954699441     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.52     Document Type: Article

References (48)

1. Otto F, Lubbert M, Stock M. Upstream and downstream targets of RUNX proteins. J Cell Biochem. 2003;89:9-18. (Pubitemid 36459094)
2. Wee HJ, Huang G, Shigesada K, Ito Y. Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Rep. 2002;3:967-974. (Pubitemid 35256471)
3. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA. 1991;88:10431-10434.
4. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113-124.
5. Guo WH, Weng LQ, Ito K, et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene. 2002;21:8351-8355. (Pubitemid 35477876)
6. Torquati A, O'Rear L, Longobardi L, Spagnoli A, Richards WO, Daniel Beauchamp R. RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery. 2004;136:310-316. (Pubitemid 39037670)
7. Pratap J, Galindo M, Zaidi SK, et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res. 2003;63:5357-5362.
8. Cameron ER, Blyth K, Hanlon L, et al. The Runx genes as dominant oncogenes. Blood Cells Mol Dis. 2003;30:194-200.
9. Thomas DM, Johnson SA, Sims NA, et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol. 2004;167:925-934.
10. Galindo M, Pratap J, Young DW, et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem. 2005;280:20274-20285.
11. Young DW, Hassan MQ, Pratap J, et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature. 2007;445:442-446.
12. Zaidi SK, Pande S, Pratap J, et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci U S A. 2007;104:19861-19866.
13. Eliseev RA, Dong YF, Sampson E, et al. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene. 2008;27:3605-3614.
14. Bertaux K, Broux O, Chauveau C, Jeanfils J, Devedjian JC. Identification of CBFA1-regulated genes on SaOs-2 cells. J Bone Miner Metab. 2005;23:114-122.
15. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene. 2003;321:1-15.
16. Smith E, Frenkel B, MacLachlan TK, et al. Post-proliferative cyclin E-associated kinase activity in differentiated osteoblasts: inhibition by proliferating osteoblasts and osteosarcoma cells. J Cell Biochem. 1997;66:141-152.
17. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16,and p18 genes in osteosarcoma. Cancer Genet Cytogenet. 1996;86:136-142. (Pubitemid 26074804)
18. Kilbey A, Blyth K, Wotton S, et al. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res. 2007;67:11263-11271.
19. Musat M, Vax VV, Borboli N, et al. Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res. 2004;32:34-62.
20. Forget A, Ayrault O, den Besten W, Kuo ML, Sherr CJ, Roussel MF. Differential post-transcriptional regulation of two Ink4 proteins, p18(Ink4c) and p19(Ink4d). Cell Cycle. 2008;7.
21. Kim SA, Kim SW, Chang S, Yoon JH, Ahn SG. 5′-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett. 2008.
22. Kouraklis G, Katsoulis IE, Theocharis S, et al. Does the Expression of Cyclin E, pRb, and p21 Correlate with Prognosis in Gastric Adenocarcinoma? Dig Dis Sci. 2008.
23. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem. 2000;275:651-656.
24. Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Biochem. 2006;98:54-64.
25. Westendorf JJ, Zaidi SK, Cascino JE, et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002;22:7982-7992.
26. Zaidi SK, Sullivan AJ, Medina R, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. Embo J. 2004;23:790-799.
27. Drissi H, Hushka D, Aslam F, et al. The cell cycle regulator p27kip1 contributes to growth and differentiation of osteoblasts. Cancer Res. 1999;59:3705-3711.
28. Zhang HW, Ding J, Jin JL, et al. Defects in Mesenchymal Stem Cell Self-Renewal and Cell Fate Determination Lead to an Osteopenic Phenotype in Bmi-1 Null Mice. J Bone Miner Res. 2009.
29. Urano T, Yashiroda H, Muraoka M, et al. p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta1. J Biol Chem. 1999;274:12197-12200.
30. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep. 2008;9:878-884.
31. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57KIP2: "Kip"ing the Cell under Control. Mol Cancer Res. 2009.
32. Chang SF, Chang TK, Peng HH, et al. BMP-4 induction of arrest and differentiation of osteoblast-like cells via p21 CIP1 and p27 KIP1 regulation. Mol Endocrinol. 2009;23:1827-1838.
33. Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D. Osteoblast apoptosis and bone turnover. J Bone Miner Res. 2001;16:975-984.
34. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998;13:793-802.
35. Kitajima I, Soejima Y, Takasaki I, Beppu H, Tokioka T, Maruyama I. Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts. Bone. 1996;19:263-270.
36. Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med. 1999;134:222-231.
37. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-377. (Pubitemid 32900529)
38. Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer. 2004;109:661-667. (Pubitemid 38405611)
39. Nakayama Y, Kato N, Nakajima Y, Shimizu E, Ogata Y. Effect of TNF-alpha on human osteosarcoma cell line Saos2--TNF-alpha regulation of bone sialoprotein gene expression in Saos2 osteoblast-like cells. Cell Biol Int. 2004;28:653-660. (Pubitemid 39423674)
40. Pucci B, Bertani F, Karpinich NO, et al. Detailing the role of Bax translocation, cytochrome c release, and perinuclear clustering of the mitochondria in the killing of HeLa cells by TNF. J Cell Physiol. 2008;217:442-449.
41. Hellwig CT, Kohler BF, Lehtivarjo AK, et al. Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cycloheximide-induced caspase activities during apoptosis initiation. J Biol Chem. 2008;283:21676-21685.
42. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956-3964.
43. Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem. 2002;277:2695-2701. (Pubitemid 34953297)
44. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab. 2005;288:E1011-1018.
45. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278:50259-50272.
46. Tintut Y, Parhami F, Le V, Karsenty G, Demer LL. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem. 1999;274:28875-28879.
47. Bertaux K, Broux O, Chauveau C, Hardouin P, Jeanfils J, Devedjian JC. Runx2 regulates the expression of GNAS on SaOs-2 cells. Bone. 2006;38:943-950.
48. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5:376-387. (Pubitemid 40637829)